Market Overview

My goal is to be on stage with my computer and let you
see my screen and make sure you know what buttons to
press, where you’re getting in & out, how to calculate
risk, your targets — all of those things.
It’s real-life trading. Make sure you sign up!
- Jerremy Newsome
GET TICKETS

AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentation at the American Society of Regional Anesthesia and Pain Medicine Meeting

Share:

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, announced today that a moderated poster presentation will be made at the Emerging Technology session of the American Society of Regional Anesthesia and Pain Medicine (ASRA) 14th Annual Pain Medicine Meeting to be held November 19th to November 21st at the Fontainebleau Miami Beach in Miami, Florida. The annual ASRA meeting is the foremost scientific and educational event on invasive and non-invasive targeted therapies in pain medicine and brings together nearly 1,000 national and international thought leaders. Pamela Palmer, M.D. Ph.D., AcelRx Co-founder and Chief Medical Officer, will present safety and efficacy data from a Phase 3 trial, SAP301, evaluating the sufentanil sublingual 30 mcg tablet, or ARX-04, for the treatment of acute pain following ambulatory surgery.

Details on the presentation times are as follows:

Thursday, November 19, 2015 – Emerging Technology Moderated Poster Session, MP-02, Presentation time 10:45-12:45pm (local time), Splash 13

Authors:
Harold Minkowitz, MD, Shankar Lakshman, MD, Timothy Melson, MD, David Leiman, MD, Karen DiDonato, MSN, RN and Pamela Palmer, MD, PhD

Title:
Safety and Efficacy Subgroup Analysis by Age of Sufentanil Sublingual 30 mcg Tablets for the Treatment of Acute Pain following Outpatient Abdominal Surgery

Posted-In: News FDA

 

Related Articles (ACRX)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

Peter Brandt's Conviction Dollar Trade Will Surprise You – Although It Shouldn't

Shorts Pile Into Some Of This ETF's Holdings